+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Adalimumab Market 2020-2026

  • PDF Icon


  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129779
Global Adalimumab Drug Market Size, Share & Trends Analysis Report, By Disease (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis, and others), By Type (Branded and Generic) and Forecast, 2020-2026
The adalimumab drug market is expected to show negative growth during the forecast period 2020-2026. It is a drug used for the treatment of arthritis, Crohn's disease, ulcerative colitis, and other diseases. The drug is sold by AbbVie Inc., under the brand name of Humira. Rising incidence of arthritis, Crohn’s diseases, and increasing per capita healthcare expenditure in the emerging economies are expected to create a positive growth to the market, however; loss of branded drug patent of AbbVie Inc. is a key factor for the downfall in revenue of the drug. The company has lost its EU patent in October 2018 and the initial US composition patent in December 2016. In order to maintain the monopoly of the drug till 2023, the company has made agreements with other biosimilar manufacturing companies including Boehringer Ingelheim International GmbH, Novartis AG, Amgen Inc. After 2023, a significant drop in the Humira revenue is expected in the US. Besides, the availability of alternatives to adalimumab is also expected to restrain market growth in the near future.

The global adalimumab market is segmented based on disease and type. By disease, the market is divided into rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and others. By type, the market is bifurcated into branded and generic drugs. The generic drug market is expected to witness a lucrative growth rate during the forecast period.

On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to hold the major market share due to significant sales of Humira in the US. Europe is expected to show a modest growth rate in the market as companies are shifting from branded Humira to its biosimilars. As per NHS, UK spends around $485 million on Humira each year for 46,000 patients, which after shifting to a biosimilar will be reduced to nearly $181 million. Asia-Pacific is expected to showcase significant growth during the forecast period. The availability of biosimilars of the Humira is expected to provide significant growth to the region.

The adalimumab market is consolidated in nature and the major players operating in the market include AbbVie Inc., Novartis AG, Amgen Inc., Boehringer Ingelheim International GmbH. The market players are adopting growth strategies including mergers and acquisitions, product launches, and partnerships and collaborations, to gain a competitive advantage in the market.

Research Methodology

The market study of the global adalimumab market is incorporated by extensive primary and secondary research. Secondary research has been conducted to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts to amplify the added validity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report provides in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:
  • Global Adalimumab Market Research and Analysis, By Disease
  • Global Adalimumab Market Research and Analysis, By Type

The Report covers:
  • Comprehensive research methodology of the Global Adalimumab Market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Adalimumab Market.
  • Insights about market determinants which are stimulating the Global Adalimumab Market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdowns
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. AbbVie Inc Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Amgen Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Boehringer Ingelheim International GmbH Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Samsung Bioepis Co. Ltd Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Terumo Corp. Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Adalimumab Market by Disease
5.1.1. Rheumatoid arthritis
5.1.2. Psoriatic arthritis
5.1.3. Crohn's disease
5.1.4. Ulcerative colitis
5.1.5. Others
5.2. Global Adalimumab Market by Type
5.2.1. Branded
5.2.2. Generic
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles1. AbbVie Inc.2. Alvotech hf3. Amgen Inc.4. Bio-Thera Solutions Ltd.5. Boehringer Ingelheim International GmbH6. Bristol-Myers Squibb Co.7. Cadila Healthcare Ltd.8. Emcure Pharmaceuticals Ltd.9. Fujifilm Kyowa Kirin Biologics Co. Ltd.10. Hetero Healthcare Ltd.11. Innovent Biologics, Inc.12. Merchant Logo13. Novartis International AG (Sandoz)14. Pfizer Inc.15. Reliance Life Sciences Pvt. Ltd.16. Samsung Bioepis Co. Ltd17. Terumo Corp.18. Torrent Pharmaceuticals Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Alvotech hf
  • Amgen Inc.
  • Bio-Thera Solutions Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Cadila Healthcare Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Fujifilm Kyowa Kirin Biologics Co. Ltd.
  • Hetero Healthcare Ltd.
  • Innovent Biologics, Inc.
  • Merchant Logo
  • Novartis International AG (Sandoz)
  • Pfizer Inc.
  • Reliance Life Sciences Pvt. Ltd.
  • Samsung Bioepis Co. Ltd
  • Terumo Corp.
  • Torrent Pharmaceuticals Ltd.